Description

• Application: Development of a multiparticulate drug delivery system for in situ amorphisation.: This study explores the creation of a multiparticulate drug delivery system using sodium dihydrogen phosphate to induce in situ amorphisation, enhancing the bioavailability of poorly water-soluble drugs (Holm et al., 2022).
• Analysis Note: Purity (metallic): ≥ 99.99 %Assay (acidimetric): ≥ 99.0 %Spec. Absorbance A at 260 nm (2 cm; 10 %): ≤ 0.020Chloride (Cl): ≤ 5 ppmSulfate (SO₄): ≤ 30 ppmTotal nitrogen (N): ≤ 10 ppmAs (Arsenic): ≤ 0.05 ppmBa (Barium): ≤ 10.0 ppmCa (Calcium): ≤ 0.50 ppmCd (Cadmium): ≤ 0.010 ppmCe (Cerium): ≤ 0.010 ppmCo (Cobalt): ≤ 0.010 ppmCs (Cesium): ≤ 5 ppmCu (Copper): ≤ 0.010 ppmEu (Europium): ≤ 0.010 ppmFe (Iron): ≤ 0.05 ppmHg (Mercury): ≤ 0.05 ppmK (Potassium): ≤ 5.0 ppmLa (Lanthanum): ≤ 0.010 ppmLi (Lithium): ≤ 1.0 ppmMg (Magnesium): ≤ 0.50 ppmMn (Manganese): ≤ 0.010 ppmNi (Nickel): ≤ 0.010 ppmPb (Lead): ≤ 0.010 ppmRb (Rubidium): ≤ 5.0 ppmSm (Samarium): ≤ 0.010 ppmSr (Strontium): ≤ 0.50 ppmTl (Thallium): ≤ 0.01 ppmY (Yttrium): ≤ 0.010 ppmYb (Ytterbium): ≤ 0.010 ppmZn (Zinc): ≤ 0.010 ppm
• Legal Information: SUPRAPUR is a registered trademark of Merck KGaA, Darmstadt, Germany